Weekly Top Ten News Stories

Array
(
    [0] => Array
        (
        )

    [1] => Array
        (
        )

)

Life sciences sector analyst Stuart Roberts reports Celldex Therapeutics (Nasdaq: CLDX) is in Phase III with a cancer vaccine which can double median overall survival for glioblastoma patients.

Westpac has added a small but key acquisition to its financing business and brokers take a look at how the bank's capital metrics shape up.

The Chartist reports a corrective phase is underway for Wesfarmers but the technicals suggest longer term investors may like to set up for some subsequent blue sky.

Brokers are toughening their stance on Cochlear after the company delivered guidance for no profit growth in FY14.

Peter Switzer of the Switzer Super Report suggests interest rates in Australia will have to return to normal before bank deposits again offer better value than stocks.

Michael Gable of Fairmont Equities suggests that while any more negatives out of Washington might see another dip, BHP should otherwise look to $40 once more.

Weekly update on recommendation, target price, and earnings forecast changes.

By Rudi Filapek-Vandyck, Editor FNArena Ever since I warned investors in 2008 the temporarily loss of sanity and good judgment by the world's investment community on global oil prices would lead to many losing their shirt from owning shares in energy stocks, the secto

Saxo Bank believes a global slowdown is imminent as QE is not working, while Morgan Stanley remains positive on Australia from FY15.

The uranium market is unfortunately in relative demand-supply balance, participants concluded at a conference. No change to weekly prices.